The identification of proteins that are preferentially expressed on the membrane of metastatic tumor cells is of fundamental importance in cancer research. Here, we report the systematic comparison of the membrane proteome of two closely related murine teratocarcinoma cell lines (F9B9 and F9DR), of which only one (F9DR) is capable of forming liver metastases in vivo. The proteomic methodology used in this study featured the surface protein biotinylation on tumor cells followed by protein purification on streptavidin resin and relative quantification of corresponding tryptic peptides by mass spectrometric procedures. The study allowed the identification of 998 proteins and the determination of their relative abundance. Proteins previously known to be associated with metastatic spread were found to be either up-regulated (e.g., synaptojanin-2) or down-regulated (e.g., Ceacam1) in F9DR cells. A dramatic increase in abundance at the cell membrane was observed for a broad variety of proteins (e.g., highmobility group protein B1), which were mainly thought to reside in intracellular compartments, a finding that was confirmed using confocal laser scanning microscopy and immunochemical analysis of cell cultures. Furthermore, we showed by microautoradiographic analysis that certain target proteins can readily be reached by intravenously administered radiolabeled antibodies. Finally, we showed that the most promising antigens for antibody-based pharmacodelivery approaches are strongly and selectively expressed on the surface of tumor cells in three different syngeneic mouse models of liver metastases. Taken together, our results indicate that the expression of intracellular proteins on the membrane of metastatic cells is a feature much more common than previously expected.
Introduction
In the last decade, DNA microarrays have become a standard tool for the molecular analysis of cancer, providing global profiles of transcription that reflect the origin (1), stage of development (2) , drug sensitivity (3) , and metastatic potential of tumor cells (4) . The ability to complement these transcriptomic approaches with methods that analyze the proteome (5, 6 ) is crucial for the identification of proteins that may serve as targets for the development of antibody-based therapeutic strategies. Such proteomic research activities are particularly needed for the characterization of gene products contributing to the metastatic potential of cancer cells, considering the fact that the majority of cancer-related deaths are associated with the metastatic spread of the disease (7) .
Monoclonal antibodies (mAb) represent promising and highly versatile tools for the development of more selective anticancer therapeutic strategies. The activity of intact immunoglobulins may rely on the inhibition of functional proteins, the induction of signaling events, complement activation, and/or the recruitment of immune cells at the tumor site (8) . By contrast, antibody derivatives can be used for the targeted delivery of bioactive moieties to cancer sites in vivo (9, 10) . Because mAbs need to recognize accessible antigens to display a therapeutic activity, proteomic technologies that allow the identification and relative quantification of membrane proteins, secreted proteins, and extracellular matrix components are particularly important for the development of innovative antibody-based anticancer strategies. However, conventional proteomic approaches that rely on two-dimensional gel electrophoresis encounter difficulty analyzing membraneassociated and low abundance proteins (11) . On the other hand, recent gel-free proteomic methods either are inherently not quantitative (e.g., MudPit; ref. 12) or may impose stringent requirement on the homogenous chemical modification of target proteins (e.g., ICAT or iTRAQ; ref. 13) .
To address these limitations, we have developed a proteomic technology (termed two-dimensional peptide mapping; refs. 6, [14] [15] [16] for the identification and relative quantification of accessible proteins in closely related cell culture models. This methodology features the covalent biotinylation of accessible proteins using reactive ester derivatives of biotin followed by sample lysis, protein capture on streptavidin resin, proteolytic digestion, and comparative analysis of the resulting peptides based on nano-high-performance liquid chromatography (HPLC) and mass spectrometric (MS) procedures. This methodology can be applied to the study of accessible proteins in organs and tumors using in vivo (17) (18) (19) or ex vivo (20, 21) perfusion procedures with reactive biotin ester solutions.
In this article, we report the comparative analysis of the cell surface proteome of two closely related murine tumor cell lines (F9B9 and F9DR; ref. 22) , of which only the latter is capable of forming liver metastases in immunocompetent Sv129Ev mice after intravenous injections of tumor cells. Our findings reveal substantial changes in the abundance of proteins that have previously been associated with metastatic spread of cancer. However, surprisingly, we have discovered that certain intracellular proteins become exposed on the cell surface of the aggressive F9DR cell line. This unexpected property was confirmed to occur also in vivo, evidenced by the immunofluorescence study of four different syngeneic mouse models of liver metastasis, and by the in vivo targeting experiments with radiolabeled antibody preparations.
In summary, we have observed that the expression of intracellular proteins on the membrane of metastatic cells is a feature much more common than previously expected.
Materials and Methods
Cell culture and surface biotinylation. The two murine teratocarcinoma cell lines F9B9 (nonmetastatic cell line) and F9DR (metastatic cell line; ref. 23) , which have been kindly provided by Dario Rusciano (SIFI), were propagated on gelatin-coated (F9B9) or uncoated (F9DR) cell culture flasks. Cell were cultured in DMEM (Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies) and 1% antibiotic-antimycotic solution (Life Technologies; containing 10,000 units/mL penicillin, 10,000 Ag/mL streptomycin, and 25 Ag/mL amphotericin B).
For each cell type, five 300 cm 2 cell culture flasks containing confluent F9B9 and F9DR teratocarcinoma cells were used for cell surface biotinylation as described (16) . All solutions used for biotinylation were cooled to 4jC. Cells were washed once with PBS followed by incubation with PBS containing 880 Amol/L EZ-link sulfo-NHS-SS-biotin (Pierce) for 5 min at room temperature on a shaker. To terminate the biotinylation reaction, Trizma base (Fluka) was added to a final concentration of 8.8 mmol/L. Cells were detached into a 10 mmol/L EDTA/PBS solution containing 1.33 mmol/L oxidized glutathione (Fluka). After centrifugation, cell pellets were washed once with PBS containing 0.66 mmol/L oxidized glutathione.
Isolation, elution, and digestion of biotinylated proteins. For each 300 cm 2 cell culture flask, cells were lysed for 30 min on ice with 2 mL lysis buffer [2% (w/v) NP-40 substitute (Fluka), 0.2% (w/v) SDS, 1Â complete E protease inhibitor (Roche Diagnostics), 10 mmol/L EDTA, and 108 Amol/L oxidized glutathione in PBS]. The cell lysate was centrifuged for 10 min at 16,100 Â g and the cleared supernatant was used for purification of biotinylated proteins on streptavidin-Sepharose high-performance resin (GE Healthcare). , and 1.6 Ag sequencinggrade modified trypsin (Promega) was added. The digestion was carried out over night at 37jC in a thermomixer (Eppendorf) at 1,000 rpm. Resulting tryptic peptides were desalted, purified, and concentrated with C18 microcolumns (ZipTip C18; Millipore) according to the manufacturer's instructions. The two split samples were pooled, lyophilized, and stored at À20jC.
Reverse-phase HPLC. Tryptic peptides were separated by nano-reversephase HPLC using an UltiMate nanoscale LC system and a FAMOS microautosampler (LC Packings) controlled by the Chromeleon software (Dionex). Mobile phase A consisted of 2% acetonitrile and 0.1% trifluoroacetic acid in water, and mobile phase B consisted of 80% acetonitrile and 0.1% trifluoroacetic acid in water. The flow rate was set to 300 nL/min. Each of the 10 samples was dissolved in 16.7 AL buffer A, and 5 AL were loaded on the column (15 cm Â 75 Am i.d., C18 PepMap 100, 3 Am, 100 Å; LC Packings). The peptides were eluted with a gradient of 0% buffer B for 3 min, 0% to 60% buffer B for 81 min, 60% to 100% buffer B for 10 min, and 100% buffer B for 5 min; the column was equilibrated with 100% buffer A for 20 min before the next sample was processed. The eluted fractions were mixed with a solution of 3 mg/mL a-cyano-4-hydroxycinnamic acid, 277 pmol/mL of each of the three internal standard peptides (neurotensin, angiotensin I, and adrenocorticotropic hormone fragment 1-17; all from Sigma), 70% acetonitrile, and 0.1% trifluoroacetic acid in water and were deposited on a 192-well matrix-assisted laser desorption/ionization (MALDI) target plate using the online Probot system (Dionex). The flow of the MALDI matrix solution was set to 1,083 nL/min. Thus, fractions collected each 20 s contained 361 nL MALDI-matrix solution and 100 nL sample. The final concentration of each of the three standard peptides was 100 fmol/spot.
MALDI-time of flight/time of flight. MALDI-time of flight (TOF) and MALDI-TOF/TOF MS analyses were carried out with the 4700 Proteomics Analyzer (Applied Biosystems). Peptide masses were acquired over a range from 750 to 4,000 m/z, with a focus mass of 2,000 m/z. MS spectra were summed from 2,000 laser shots from a Nd:YAG laser operating at 355 nm and 200 Hz. An automated plate calibration was done using five peptide standards (masses 900-2,400 m/z; Applied Biosystems) in six calibration wells. This plate calibration was used to update the instrument default mass calibration, which was applied to all MS and tandem MS spectra. Furthermore, an internal calibration of each MS spectrum using the three internal standard peptides added to the MALDI matrix was done. A maximum of 15 precursors per sample well with a signal-to-noise ratio of >120 was automatically selected for subsequent fragmentation by collisioninduced dissociation. Tandem MS spectra were summed from 2,500 to 4,000 laser shots. Spectra were processed and analyzed by the Global Protein Server Workstation (Applied Biosystems), which uses internal MASCOT (Matrix Science) software for matching MS and tandem MS data against databases of in silico digested proteins. The MASCOT search parameters were (a) mouse database downloaded from the European Bioinformatics Institute homepage 3 Two-dimensional peptide mapping. The MALDI-TOF MS data were used to establish two-dimensional peptide maps with the Spectational software (16) , which plots HPLC fractions on the Y axis and the m/z ratios of the measured peptides on the X axis. In addition, the software translates the logarithmic values of the normalized intensities to a grayscale. The normalization is done with respect to the internal standard peptide neurotensin. ASCII spectrum files for the creation of two-dimensional peptide maps were produced using Data Explorer V4.6 software (Applied Biosystems).
Relative quantification with nQuant. MALDI-TOF MS data combined with results from the Global Protein Server Workstation database search were used for relative quantification using the newly developed nQuant software. At first, this software normalizes each peak in a MS spectrum to the internal standard neurotensin. Then, nQuant sums up the normalized peak intensities from a peptide eluting in several HPLC fractions and compares it with the same peptide in another sample. The ratio of these two normalized peak intensity sums is used as relative quantity. A comprehensive description of this technology will be published soon.
Immunocytochemistry/immunofluorescence microscopy. Immunofluorescence analysis was done on methanol fixed cells grown on 0.8 cm Lab-Tek chamber slides (Nunc) using anti-adenylate kinase 2 (Ak2), antidipeptidyl peptidase 4 (Dpp4), anti-Syk (Santa Cruz Biotechnology), antihigh-mobility group protein B1 (Hmgb1 ; Abcam), anti-complement regulatory protein Crry (Crry; BD Pharmingen), and anti-a-actinin-4 (Actn4; Invitrogen) antibodies. The corresponding secondary antibodies were labeled with Alexa Fluor 546 (Invitrogen). Nuclei were counterstained with Hoechst 33342 (Invitrogen). Slices were mounted with Glycergel mounting medium (Dako) and analyzed with an Axiovert S100 TV microscope (Zeiss).
Immunocytochemistry/confocal laser scanning microscopy. Confocal laser scanning microscopy was done on methanol-fixed cells grown on 4.2 cm 2 Falcon cell culture inserts (BD Biosciences) using the antibodies indicated above. Secondary antibodies were labeled with Alexa Fluor 546, nuclei were counterstained with 1 Ag/mL 4 ¶,6-diamidino-2-phenylindole, and Alexa Fluor 660 phalloidin (all from Invitrogen) was used for probing F-actin. Slices were mounted with mounting medium [70% (v/v) glycerol, 30 mmol/L Tris-HCl (pH 9.5), 5% (w/v) n-propyl-gallate (Sigma)] and analyzed with a LSM 510 META from Zeiss. Images were further processed using the IMARIS software (Bitplane).
Microautoradiography. In vivo targeting performance of four mouse mAbs against Hmbg1, Syk, Actn4, and ovalbumin (all obtained from Abcam; ovalbumin was taken as a negative control) was evaluated by microautoradiography as described previously (24) . Briefly, mAbs in IgG format were radiolabeled with 125 I using the Iodogen method and injected into the tail vein of immunocompetent 129SvEv mice bearing F9 liver metastases (10 Ag IgG; 10 ACi). Seventy-two hours after the intravenous injection of the radiolabeled antibodies, mice were sacrificed and tumors were embedded and frozen in OCT medium (MICROM). Ten micrometer sections were cut and fixed with ice-cold acetone. Sections were then coated with NBT Kodak autoradiography emulsion, dried, and stored at 4jC in the dark for f10 weeks. The autoradiography emulsions were developed (Kodak Developer D-19) for 4 min and fixed (Kodak EASTMAN Fixer) for 5 min. Finally, slides were rinsed with deionized water and counterstained with hematoxylin (Sigma).
Mouse models of liver metastases. All animal experiments were approved by either the Swiss or the Italian Veterinary Office and done in accordance with national and international laws and regulations. The intravenous injection of F9DR cells into male Sv129Ev mice (Charles River Laboratories) was done as described in ref. 19 . The intrasplenic injection of Colon38 and SL4 cells into female C57BL/6J mice (Harlan) was done as described in ref. 25 . The subcutaneous injection of M5076 cells into female C57BL/6J mice (Harlan) was done as described in ref. 26 . Immunofluorescence/confocal laser scanning microscopy. Confocal laser scanning microscopy was done on acetone-fixed cryostat sections (10 Am) of freshly frozen tissue specimens of liver metastases deriving from the intravenous injection of F9DR cells, the subcutaneous injection of M5076 cells, and the intrasplenic injection of SL4 and C38 cells. Immunofluorescent staining with anti-Hmgb1 and anti-Syk antibodies (indicated above) was done according to standard protocols with an additional blocking step using goat anti-mouse IgG F(ab) fragment (Jackson ImmunoResearch). As secondary antibody, goat anti-mouse Alexa Fluor 488 (Invitrogen) was used. Nuclei were counterstained with 1 Ag/mL 4 ¶,6-diamidino-2-phenylindole (Invitrogen). Slides were mounted with fluorescent mounting medium (DAKO) and analyzed with a LSM 510 META from Zeiss. Images were further processed using the ImageJ software. 4 
Results
Two-dimensional peptide mapping analysis of F9B9 ad F9DR cell cultures. F9DR cells represent a subline of the murine teratocarcinoma cell line F9B9 (23) , which has acquired a striking potential to form liver metastases following intravenous administration into syngeneic immunocompetent Sv129Ev mice (ref. 22 ; Fig. 1A and B, insets) . We performed surface biotinylation of parallel cultures of F9B9 and F9DR cells (in each case, 5 parallel cultures) using published methodologies (14, 16) . The resulting biotinylated proteins were recovered by cell lysis in the presence of strong detergents and captured on streptavidin resin. After elution, biotinylated proteins were subjected to tryptic digestion, yielding peptides that were separated by nano-reverse-phase HPLC and analyzed by MALDI-TOF in the presence of internal standards for quantification and by MALDI-TOF/TOF for identification (Fig. 1A and B) . The resulting two-dimensional peptide maps were used for the computer-assisted identification of proteins, which were consistently up-regulated or down-regulated in F9DR cells. Figure 1C and D shows the reproducibility of nano-reverse-phase HPLC chromatographic profiles for the five tryptic digests for each cell as well as representative MALDI-TOF spectra in triplicate for peptides, which exhibited differential surface expression in the two cell lines. A more detailed analysis of two nonregulated, three F9B9 up-regulated, and three F9DR up-regulated proteins is shown in Supplementary Fig. S1 .
In the course of this proteomic investigation, a total of almost 1,000 proteins was identified, corresponding to 695 peptide sets, of which 520 peptide sets matched to a single protein (Supplementary  Tables S1 and S2) . Table 1 shows a list of selected proteins displaying differential abundance in the two-dimensional peptide mapping analysis. This list features the down-regulation in F9DR cells of proteins that have been associated with inhibition of metastatic spread [e.g., tyrosine protein kinase SYK (Syk)] or to participate in cell-cell interactions (e.g., Dpp4). Similarly, we observed the up-regulation in F9DR cells of proteins that have previously been associated with an invasive phenotype of cancer (e.g., Hmgb1, Ak2 homologue, and Actn4).
Analysis of the putative subcellular localization of the proteins corresponding to the 84 regulated peptide sets revealed, as expected, a strong enrichment in plasma membrane proteins and extracellular space components in F9B9 cells (71%; Supplementary  Fig. S2A ). By contrast, we observed a striking enrichment for 4 http://rsb.info.nih.gov/ij/ Figure 2 . Immunofluorescence analysis and characterization of the subcellular localization of the six selected differentially regulated proteins. The proteins Actn4, Hmgb1 , and Ak2 were identified in the proteomic analysis to be up-regulated in F9DR-cells, which was confirmed by immunofluorescence (left and middle columns ). By contrast, the proteins Syk, Dpp4 , and Crry have been found to be up-regulated in F9B9 cells. Bar, 100 Am. Two-color confocal laser scanning microscopy (CLSM ) images (red, antibody against selected protein; blue, 4 ¶,6-diamidino-2-phenylindole) displaying x-y (big display ), x-z (below ), and y-z (on the right side) optical sections of representative areas (right column ). Alongside, the corresponding three-color images (actin stained green, nuclei stained blue , and listed proteins stained red) are presented. Antibodies against Actn4, Hmgb1 , and Ak2 were used to stain F9DR cells; antibodies against Syk, Dpp4 , and Crry were used to stain F9B9 cells. All proteins are found, among other things, in the plasma membrane. Bar, 15 Am.
proteins with a putative nuclear and cytoplasmic localization in F9DR cells (74%; Supplementary Fig. S2B) .
Characterization of subcellular localization of selected regulated proteins. To confirm that the surface display of intracellular proteins in F9DR cultures was a real event and not merely an artifact of cell lysis before the in vitro biotinylation procedure, we performed a confocal laser scanning microscopic analysis of F9DR and F9B9 cells using fluorescence-labeled antibodies specific to proteins that were found to be up-regulated (Actn4, Hmgb1, and Ak2) or downregulated (Syk, Dpp4, and Crry) on the surface of F9DR cells. Figure 2 (left and middle columns) shows a two-color fluorescence microscopic analysis of F9DR and F9B9 cells, revealing as expected an up-regulation of Actn4, Hmgb1, and Ak2 and a downregulation of Syk, Dpp4, and Crry in F9DR cells. To confirm protein localization on the plasma membrane, we analyzed optical sections of the confocal microscopic images, revealing a presence not only in the cytoplasm but also on the tumor cell membrane for all six proteins (Fig. 2, right column; Supplementary Fig. S3A-F) . Two of them (Actn4 and Ak2) have previously been postulated to be located exclusively in cytoplasmic or mitochondrial compartments, respectively.
To further investigate whether proteins overexpressed in the F9DR cells are also surface-expressed in vivo (and thus accessible to mAbs), we performed a microautoradiography study. To this end, we labeled four different mAbs with 125 I and injected them intravenously into immunocompetent 129SvEv mice bearing F9 liver metastases. The microautoradiographic analysis of liver metastasis sections, obtained 72 h post-injection, confirmed the accumulation of the antibodies against Hmgb1 and Syk (Fig. 3) around nests of tumor cells. By contrast, antibodies specific to Actn4 ( found to be up-regulated in liver metastases) and ovalbumin (used as negative control) exhibited no preferential accumulation in metastases (Fig. 3) . Finally, to assess the generality of our observation, we studied liver metastases of M5076 reticulosarcoma cells and the two colon carcinoma cell lines Colon38 and SL4, developed by either subcutaneous (M5075) or intrasplenic (Colon38 and SL4) injection of tumor cells (Fig. 4) . In addition to F9 liver metastases, we observed a strong membranous staining of metastatic cells in the liver lesions of colorectal cancer origin (Colon38 and SL4) and for the reticulum cell sarcoma (M5076). Whereas Hmgb1 and Syk were clearly detectable in all four models of liver metastasis, Hmgb1 was found to be more strongly expressed in F9 and M5076 lesions, whereas Syk was also abundant in C38 metastases.
Discussion
Metastatic spread of cancer is responsible for the majority of cancer-related deaths (7) . The identification of accessible proteins, which are up-regulated in the metastatic process, may facilitate the development of mAbs for pharmacodelivery strategies. We have performed a comparative proteomic analysis of nonmetastatic (F9B9) and metastatic (F9DR) teratocarcinoma cell lines, applying two-dimensional peptide mapping procedure (6, (14) (15) (16) ) and a newly developed software (nQuant), which facilitates the relative protein quantification by comparing MALDI-TOF signal intensities with those of internal standard peptides. In Table 2 , we summarized some features of selected proteins that exhibited a different expression in F9B9 and F9DR cells and that have previously been implicated in cancer growth and metastatic spread. Unexpectedly, we found several intracellular proteins to be displayed on the surface of tumor cells with metastatic potential and we confirmed this finding in vivo in four different models of liver metastasis.
Antibody-based pharmacodelivery strategies have thus far mainly focused on membrane proteins as target antigens of choice (27) . Alternatively, certain intracellular proteins (e.g., histones) have been found to be abundant at sites of necrosis and thus potentially amenable for targeted delivery applications (28) , in consideration of the fact that necrosis is a rare event in the healthy adult but a characteristic feature of aggressive solid tumors. More recently, we and others have focused our attention to components of the modified extracellular matrix (e.g., splice isoforms of fibronectins and tenascins) as suitable targets for antibody-based pharmacodelivery applications (9, 29) . Indeed, as these targets are often found in the subendothelial extracellular matrix, we have extensively shown, both in animal models of cancer and in patients with metastatic disease, that markers of angiogenesis such as alternatively spliced domains of fibronectin and of tenascin-C may be efficiently targeted by human mAbs in a variety of different malignancies (19, 30) . Although we have investigated a variety of different antibody functionalization strategies in preclinical models of cancer (29, 30) , the most striking therapeutic results have thus far been observed with radiolabeled antibodies (31) and with immunocytokines (32) . For this reason, derivatives of the L19 antibody (specific to the extra-domain B of fibronectin) and the F16 antibody (specific to the extra-domain A1 of tenascin-C) have been moved to clinical trials in patients with cancer, with promising therapeutic results (33) .
The structural and functional study of intracellular proteins such as Hmgb1, a-enolase, and nucleolin (34) indicates that certain proteins may be expressed in different cell compartments in healthy cells and cancer cells, with distinct functional roles. Based on surface protein biotinylation and immunofluorescence data, this study reveals that export of intracellular proteins to the cell surface may be a much more frequent process yet restricted to certain pathologic situations. Proteins may reach the cell surface either through active export mechanisms (by the endoplasmic reticulum/Golgi-dependent pathway), endoplasmic reticulum/ Golgi-independent protein secretion (e.g., mediated by caspase-1 or heparin sulfate proteoglycans), or by association with the membrane of neighboring cells after apoptotic or necrotic processes.
The surface accessibility of proteins such as Hmgb1 was shown not only in vitro using confocal laser scanning microscopy but also in vivo using injection of radiolabeled antibody and microautoradiographic analysis. The most promising antigens for pharmacodelivery applications (Hmgb1 and Syk) were found to be selectively and strongly expressed in 4 of 4 syngeneic mouse models of liver metastasis, thus reinforcing the concept that surface expression of certain intracellular proteins may be a general process in metastatic spread. These markers may represent ideal targets for antibody-based drug delivery strategies (8, 9) . A comparative biodistribution analysis in the same animal models (24) 5 using the well-characterized L19 and F16 antibodies (29) and new mAbs specific to Hmgb1 (or other intracellular antigens that become expressed on the surface of metastatic cells) will allow to evaluate the relative merits of these different classes of tumor antigens for antibody-based pharmacodelivery applications.
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